CoreWeave's shares slip after it unveils AI spending plans in first results since IPO
FILE PHOTO: A screen displays the company logo for CoreWeave, Inc., Nvidia-backed cloud services provider, during the company's IPO at the Nasdaq Market, in New York City, U.S., March 28, 2025. REUTERS/Brendan McDermid/File Photo
(Reuters) -CoreWeave shares fell more than 5% in premarket trading on Thursday, after the Nvidia-backed artificial intelligence company unveiled its capital expenditure plans to meet booming demand.
The data center operator, which went public in March, forecast its second-quarter capital expenditure would be in the range of $3 billion to $3.5 billion while revenue expectations were $1.06 billion to $1.1 billion.
CoreWeave's management was optimistic about the demand for its services on the post-earnings call, but brokerage MoffettNathanson said "the cost of preparing to meet this demand may spook investors" who are paying a high price for the stock.
CoreWeave, which leases computing capacity to technology companies and hyperscalers building AI models such as one of its prominent customers Microsoft, reported a more than five-fold increase in revenue to $981.6 million for the first three months of the year.
"We have also added new enterprise customers and a new hyperscaler and signed expansion agreements with several large customers, including a recent $4 billion expansion with a large AI enterprise," CoreWeave's CEO Michael Intrator said.
Its annual and second-quarter capital expenditure forecasts indicate AI spending could continue at a similar pace even as investor scrutiny sharpened after the launch of DeepSeek's low-cost AI models.
Big Tech firm Meta raised its annual capital expenditure forecast, while Alphabet reaffirmed it and a Microsoft executive also re-emphasized the company's AI spending plans in a LinkedIn post in April.
As of last close, CoreWeave's stock had surged 69% from the offer price in its March IPO. At least five brokerages have raised their price targets on the stock to between $50 and $70 following the results.
(Reporting by Jaspreet Singh in Bengaluru; Editing by Krishna Chandra Eluri)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
an hour ago
- Malaysian Reserve
Neurocrine Biosciences Appoints Lewis Choi as Chief Information Officer
SAN DIEGO, June 9, 2025 /PRNewswire/ — Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the appointment of Lewis Choi as Chief Information Officer, effective June 9, 2025. Choi, an accomplished leader with 25 years of experience in information technology and artificial intelligence, will be responsible for driving the vision and long-term strategic direction of the company's technology initiatives. 'Lewis is a proven global healthcare leader with a track record of utilizing technology to drive both cultural and technological change,' said Matt Abernethy, Chief Financial Officer, Neurocrine Biosciences. 'As we launch CRENESSITY, grow INGREZZA, and advance our pipeline, he joins Neurocrine at an exciting time when advancements in technology will play a critical role in advancing our mission to help more patients.' 'I am excited to join Neurocrine at such a pivotal time for the company,' Choi said. 'I look forward to leveraging innovative IT and digital solutions to strengthen the business and support the teams who work tirelessly to discover, develop and deliver critical treatments for patients.' Choi joins Neurocrine after a 13-year career at Thermo Fisher Scientific, most recently as the Vice President of AI Automation & Data. Previously, he was Global Vice President of Digital Platforms, Engineering & Generative AI; Vice President of Digital Solutions for APAC and Emerging Markets; and Vice President of Corporate Solutions & Integrations. Prior to that, he held IT roles at Life Technologies (prior to its acquisition by Thermo Fisher Scientific), SysGroup Inc., Serene Corporation, ADP, and Corio, Inc. and earned a Bachelor of Arts degree at the University of California, Berkeley. About Neurocrine Biosciences Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit and follow the company on LinkedIn, X, and Facebook. (*in collaboration with AbbVie) NEUROCRINE, the NEUROCRINE BIOSCIENCES Logo, YOU DESERVE BRAVE SCIENCE, INGREZZA, and CRENESSITY are registered trademarks of Neurocrine Biosciences, Inc. © 2025 Neurocrine Biosciences, Inc. All Rights Reserved. 06/2025
Free Malaysia Today
3 hours ago
- Free Malaysia Today
Huawei CEO says China's chips trail US by one generation
Huawei CEO Ren Zhengfei stated the company allocated US$25.07 billion a year to R&D, with an emphasis on compound chip innovation. (Reuters pic) BEIJING : Huawei Technologies' chips are one generation behind those of US peers but the firm is finding ways to improve performance through methods such as cluster computing, Chinese state media quoted CEO Ren Zhengfei as saying on Tuesday. The chipmaker invests 180 billion yuan (US$25.07 billion) in research annually and sees promise in compound chips – or chips made from multiple elements – Ren said in an interview in the People's Daily newspaper of the governing Communist Party. The public comments are the first from Ren or Huawei about the firm's advanced chip manufacturing efforts. US export controls since 2019 have prevented Huawei from accessing high-end chips and equipment to manufacture them. Huawei has since marketed its Ascend series of artificial intelligence chips which compete in China with offerings from US rival Nvidia, the global leader in AI chips. The US commerce department last month said use of Ascend chips would be a violation of export controls. Huawei is just one of many Chinese chipmakers, Ren said in the interview. 'The US has exaggerated Huawei's achievements. Huawei is not that great. We have to work hard to reach their evaluation,' he said. 'Our single chip is still behind the US by a generation. We use mathematics to supplement physics, non-Moore's law to supplement Moore's law and cluster computing to supplement single chips and the results can also achieve practical conditions,' he said. Cluster computing is when multiple computers work together. Moore's law refers to the speed of chip advancement.
The Star
5 hours ago
- The Star
Sunnova files for bankruptcy on residential solar woes
The logo of Sunnova Energy International Inc. is displayed on screens during the company's IPO on the floor of the New York Stock Exchange (NYSE) in New York, U.S., July 25, 2019. REUTERS/Brendan McDermid/File Photo Sunnova Energy said on Sunday it had filed for Chapter 11 bankruptcy protection in the United States, as the residential solar panel installer buckled under the pressure of mounting debt and weakening demand. Sunnova is the second residential solar company to file for bankruptcy this month, reflecting the challenges faced by the industry as it struggles to cope with higher interest rates, an incentive cut in top market California and fears of subsidy rollbacks. Last week, privately held Solar Mosaic filed for bankruptcy protection, while industry pioneer SunPower collapsed a year back. On Monday, Sunnova said it had entered into agreements with Atlas SP Partners and Lennar Homes under which it would sell certain assets to each company for a value of $15 million and $16 million respectively, pending court approval. The company will continue its regular operations throughout the sale process. Sunnova filed for protection in the Bankruptcy Court for the Southern District of Texas after warning in March that it might not be able to continue as a going concern. The company listed its estimated assets and liabilities in the range of $10 billion to $50 billion and had a total debt of $10.67 billion as of December 31, according to a court filing. Sunnova said last week it would lay off about 55% of its workforce, or 718 employees, in a bid to cut spending. Earlier this month, its unit, Sunnova TEP Developer, had also filed for Chapter 11 bankruptcy protection. President Donald Trump's administration, which is pushing to maximise oil and gas production, cancelled a partial loan guarantee of $2.92 billion last month that was awarded to Sunnova by the Biden administration. Companies that put solar panels on U.S. homes said last month that a Republican budget bill that has advanced in Congress could deal a massive blow to the industry by eliminating a generous subsidy for homeowners that had buttressed the industry's growth. "Depending on what happens with the tax bill in Congress, the conditions in this market may become even worse in 2026, because Congress is considering ending the tax credit for residential solar," Raymond James analyst Pavel Molchanov said. - Reuters
